Puenrui Bio Launches Next-Gen SuperPDTX™ Technology, Ushering in an Era of Mass-Personalized Precision Oncology

VCBeat (WeChat ID: vcbeat) has learned that on April 18, 2018, Nanjing Pureng Biotechnology Co., Ltd. (“Pureng Biotech”) unveiled its internationally pioneering SuperPDTX™ technology. Compared with the company’s conventional PDTX platform, this new technology represents a revolutionary innovation in terms of overall drug efficacy assessment time and patient burden, ushering in an era of mass-accessible, personalized precision oncology diagnosis and treatment.

SuperPDTX™ (PDTX, patient-derived tumor xenograft) is a pioneering and internationally leading novel method for personalized tumor pharmacodynamic testing, developed by Purui Biotech. This approach involves establishing patient-derived xenograft models in severely immunodeficient mice using primary tumor tissues obtained from surgical resection or biopsy. Subsequently, in vivo pharmacodynamic evaluations are conducted to assess various therapeutic agents or regimens, thereby identifying the optimal treatment option as a critical reference. This process significantly enhances the efficacy and safety of clinical treatments. (The protocol involves continuous drug administration for 7 days starting 3–5 days post-inoculation, followed by 3–5 days for efficacy evaluation, with a total testing duration of 10–15 days.)

SuperPDTX™, like the PDTX model, maintains consistency with the patient’s original tumor tissue in terms of vascular structure, stromal cells, growth factors, and cancer cell types. SuperPDTX™ is applied to personalized drug efficacy screening for clinical oncology patients. Compared with traditional drug screening technologies such as PDTX, CDX, MINI-PDX, and i-Chemo, it features distinct originality, shorter turnaround time, lower cost, and a higher concordance rate with clinical outcomes. SuperPDTX™ is the world’s first rapid PDTX technology based on tissue implantation; it still involves tumor tissue engraftment while preserving the original three-dimensional tumor structure and tumor microenvironment.

SuperPDTX™ delivers drug efficacy test results within 10–15 days, significantly shortening the 2–4 month turnaround time required by traditional PDTX technology, thereby enabling seamless integration with the first adjuvant chemotherapy regimen for post-operative tumor patients. Meanwhile, the cost of SuperPDTX™ is substantially reduced, with a base fee of only RMB 24,000 per case (including four drug efficacy regimens), equivalent to 15% of the base fee for traditional PDTX. SuperPDTX™ demonstrates high consistency in clinical outcomes; the concordance rate between this new technology and traditional PDTX reaches 80%, while the clinical concordance rate exceeds 70%, far surpassing the current clinical chemotherapy response rate of 25%.

According to Professor Chen Duan, the company’s Chief Scientist (Academician of the Norwegian Academy of Technological Sciences and Letters; Chair of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology), SuperPDTX™ is currently the only rapid PDTX technology that employs tissue block implantation to preserve the original tumor microenvironment. Its efficacy results more closely reflect the actual clinical conditions of patients (P0). In contrast to traditional PDTX models, which evaluate drug efficacy in P2 or P3 generations of tumor-bearing mice based on changes in tumor volume and weight, SuperPDTX™ conducts in vivo efficacy testing in P1-generation mice. It provides a more objective and accurate assessment of therapeutic efficacy through comprehensive pathological evaluation of tumors, including tumor cell morphology, tumor cell counts, the proportion of necrotic tissue, and proliferative activity per unit of tumor cells (Ki67).

The concordance rate of drug responses between SuperPDTX™ model samples and PDTX was 76.7% (23/30). Among all emerging PDTX technologies, SuperPDTX™ is currently the only rapid PDTX technology internationally that has undergone validation for concordance with both conventional PDTX and clinical outcomes.

Eight clinical regimens derived from PDTX testing results were re-validated using SuperPDTX™; among the original eight regimens, seven showed efficacy outcomes consistent with the initial PDTX findings.

TGI (Terminal Tumor Growth Inhibition Rate))=(Tumor volume in the control group-Tumor Volume in the Experimental Group)/Control group tumor volume ×100%）

Dr. Zhu Yanping, founder of Pu’enrui Biotech, stated that SuperPDTX™ is applied to personalized precision drug screening for clinical oncology patients. With an annual commercial market size exceeding RMB 40 billion, it can reduce the clinical chemotherapy inefficiency rate from 75% to below 30%, offering hope for high-quality survival to China’s vast and steadily growing population of cancer patients, while saving the country more than RMB 100 billion annually in ineffective drug expenditures.

Nanjing Purui Biotechnology Co., Ltd. is a company specializing in research and services in precision oncology. Leveraging the world-class technical platform of the Laude (Nanjing) International Institute for Translational Medicine (the medical arm of the Norwegian University of Science and Technology (China) Innovation Center (RICC)), the company conducts precision oncology research and provides related services, having developed the globally leading SuperPDTX™ technology.

Currently, the company has established China’s first tumor biobank and PDTX mouse resource library, integrating clinical phenotypes, pharmacodynamic phenotypes, and omics data in accordance with international standards. Backed by a team of renowned domestic and international professors and academicians, its precision medicine diagnostic and therapeutic technologies have reached an internationally advanced level. It is the first institution in China to provide patient-centric, one-stop precision diagnosis and treatment services.